Burkly Linda 4

What Happened Linda Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine (EDIT), received a grant of 292,856 derivative shares reported on Form 4 for the 2026-03-12 transaction date. The grant is reported at an acquisition price of $0.00 (derivative award), meaning no cash was paid by the executive at grant. This is a compensation award (option/derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-12 (Form 4 filed 2026-03-16). Filing appears within the standard two-business-day window.
• Transaction type/code: A (Grant/Award of derivative securities).
• Amount: 292,856 derivative shares reported at $0.00 per share.
• Vesting: Per footnote, the option was granted March 12, 2026 and vests in equal monthly installments over four years (April 12, 2026 through March 12, 2030).
• Shares owned after transaction: Not specified in the provided excerpt of the Form 4.
• Footnote: Vesting schedule described above (F1). No 10b5-1, tax-withholding, or late-filing flags shown in the excerpt.

Context This is a standard equity compensation grant to a senior executive and represents potential future ownership if vesting and any exercise requirements are met. Because it is a derivative award that vests over time, it does not represent an immediate cash purchase or sale and should be viewed as company compensation rather than a direct bullish or bearish trading signal.